ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
De Novo Design and Directed Evolution Refinement of Mirror-Image Protein Binders Targeting Interleukin-4.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Human interleukin-4 (IL-4) is a critical therapeutic target for allergic diseases and cancer, yet current biologics face stability and specificity limitations. We report a novel strategy combining de novo computational design with directed evolution to engineer a D-protein inhibitor targeting IL-4. Unlike stochastic screening, our approach enables epitope-specific design against the mirror-image D-IL-4 structure. Crucially, we integrated WALTZ-guided aggregation prediction into the evolution cycle to simultaneously optimize both binding affinity and solution behavior. The resulting D-protein, D-18252-evo, binds native IL-4 with nanomolar affinity (∼87 nM) and effectively blocks receptor engagement. Functional assays confirm potent inhibition of IL-4-induced STAT6 phosphorylation and cell proliferation. Furthermore, D-18252-evo exhibits exceptional biophysical properties, including high thermal stability and resistance to proteolytic degradation. This work establishes a scalable framework for generating robust mirror-image therapeutics, positioning D-proteins as a promising next-generation platform for treating cytokine-driven disorders with enhanced stability and targeted efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.